Oppenheimer analyst Suraj Kalia downgraded ResMed (NYSE: RMD) from Outperform to Perform.The analyst comments "SURMOUNT-OSA dataset was presented at ADA ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Downgrades

ResMed (RMD) July out of the money puts active as share price down 12%June 24, 2024 3:36 PM CLSA Reiterates Outperform (2) Rating on ResMed (RMD:AU) (RMD)June 24, 2024 11:29 AM ResMed, Inspire Medical slump after Lilly's positive Zepbound data; Citi downgradesJune 24, 2024 9:06 AM ResMed (RMD), Inspire Medical (INSP) sink following Lilly's sleep apnea resultsJune 24, 2024 8:47 AM Midday movers: Apple, Eli Lilly rise; Coinbase fallsJune 24, 2024 7:41 AM Citi Downgrades ResMed (RMD:AU) (RMD) to NeutralJune 24, 2024 5:30 AM CLSA Reiterates Outperform (2) Rating on ResMed (RMD:AU) (RMD)June 21, 2024 10:41 AM